Loading...

Financial Statements

Therapix Biosciences Ltd.

Therapix Biosciences Ltd. (TRPX)

0.317 €
-0.313 (-49.68%)

Income Statement

Quarter data
Year 2018 2017
Earnings Per Share Diluted 0.100.11
Net Profit Margin --
Weighted Average Shares Outstanding --
Revenue --
Weighted Average Shares Outstanding (Diluted) --
Gross Profit --
Dividend per Share --
Operating Income --
Gross Margin --
Income Tax Expense --
EBIT Margin --
Net Income --
Cost of Revenue --
Earnings Before Tax Margin --
EBIT --
EBITDA --
Profit Margin --
Operating Expenses --
Earnings Per Share Basic 0.100.11
Earnings before Tax --
Interest Expense -0.01-0.01

Balance Sheet Statement

Quarter data
Year 2018 2017 2016
Short-term debt ---
Other Assets ---
Total current liabilities 0.080.160.84
Cash and cash equivalents 0.689.201.49
Long-term debt ---
Cash and short-term investments 0.689.201.49
Total debt ---
Inventories ---
Deferred revenue ---
Goodwill and Intangible Assets ---
Total non-current liabilities ---
Total non-current assets -0.052.11
Total liabilities 1.259.574.56
Total assets 0.799.524.00
Other comprehensive income ---
Short-term investments ---
Property, Plant & Equipment Net -0.052.11
Net Debt -0.68-9.20-1.49
Investments ---
Total shareholders equity ---
Retained earnings (deficit) ---
Long-term investments ---
Receivables 0.120.280.40
Payables 0.080.160.84
Total current assets 0.799.471.89

Cash Flow Statement

Quarter data
Year 2018 2017
Investing Cash Flow -0.05-2.09
Free Cash Flow --0.02
Depreciation & Amortization --
Net cash flow / Change in cash -0.01-7.71
Effect of forex changes on cash --
Financing Cash Flow 13.181.54
Dividend payments --
Stock-based compensation --
Investment purchases --
Acquisitions and disposals --
Capital Expenditure -0.02
Operating Cash Flow --

Retained Earning Schedule

Year 2016 2017 2018
Retained Earnings (Previous Year) ---
Net Income ---
Stock Dividends ---
Dividend Paid ---
Retained Earnings ---

PPE Schedule

Year 2016 2017 2018
Gross PPE --0
Annual Depreciation -02
Capital Expenditure --0
Net PPE -02

Intangible and Goodwill Schedule

Year 2016 2017 2018
Intangible and Goodwill (Previous Year) ---
New Purchases ---
Intangible and Goodwill ---

Therapix Biosciences Ltd. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Therapix Biosciences Ltd. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.